Table 3.
Uni- and multivariate analysis for factors associated with BRFS
| Patient characteristics | n | Univariate | Multivariate | ||
|---|---|---|---|---|---|
| Median BRFS | p-value | HR (95% CI) | p-value | ||
| ISUP score | 0.580 | 1.09 (0.45–2.63) | 0.854 | ||
| ≤ 3 | 39 | NR | |||
| ≥ 4 | 61 | NR | |||
| Initial tumor stage | 0.367 | 2.06 (0.51–8.24) | 0.308 | ||
| ≤ T2 | 21 | NR | |||
| ≥ T3 | 79 | NR | |||
| Initial nodal stage | 0.538 | 0.90 (0.40–2.03) | 0.798 | ||
| N0 | 54 | NR | |||
| N1 | 42 | NR | |||
| Number of lymph node metastases | 0.277 | 1.47 (0.87–2.49) | 0.147 | ||
| 1 | 35 | NR | |||
| 2 | 23 | NR | |||
| ≥ 3 | 42 | NR | |||
| Lymph node localization | 0.060 | 2.97 (1.10–8.04) | 0.032 | ||
| Pelvic | 83 | NR | |||
| Paraaortic (± pelvic) | 17 | 32.2 | |||
| Concomitant ADT | 0.001 | 0.26 (0.09–0.76) | 0.013 | ||
| present | 83 | NR | |||
| Absent | 17 | 12.4 | |||
| ADT duration | 0.021 | 0.28 (0.11–0.73) | 0.009 | ||
| ≤ 12 months | 40 | 37.2 | |||
| > 12 months | 39 | NR | |||
| PSA persistence vs. PSA recurrence | 0.17 | 1.78 (0.47–6.74) | 0.396 | ||
| PSA persistence | 76 | NR | |||
| PSA recurrence | 22 | NR | |||
| PSA before sRT | 0.027 | 1.92 (0.81–4.57) | 0.140 | ||
| < 1 ng/ml | 42 | NR | |||
| ≥ 1 ng/ml | 58 | NR | |||
| Local recurrence | 0.336 | 1.14 (0.48–2.72) | 0.767 | ||
| No local recurrence | 71 | NR | |||
| Local recurrence | 29 | 37.6 | |||
Abbreviations: ADT androgen deprivation therapy; CI confidence interval; HR hazard ratio; ISUP International Society of Urological Pathology; NR not reached; PSA prostate-specific antigen; sRT salvage radiotherapy
Bold values denote statistical significance at the p < 0.05 level